Elicio Therapeutics, Inc. - Common Stock (ELTX)
Frequently Asked Questions About Elicio Therapeutics, Inc. - Common Stock (ELTX)
Has Elicio Therapeutics partnered with other companies or institutions?
Elicio Therapeutics has formed strategic partnerships with various academic institutions and industry players to advance its research and clinical trials. These collaborations help in the exchange of knowledge, resources, and technologies.
How can investors learn more about Elicio Therapeutics?
Investors can learn more about Elicio Therapeutics by visiting the company's official website, reviewing their public filings with the Securities and Exchange Commission, and following updates on financial news platforms. Additionally, participation in investor conferences can provide further insights.
How does Elicio Therapeutics ensure patient safety during trials?
Elicio Therapeutics adheres to strict protocols outlined by regulatory authorities to ensure patient safety during its clinical trials. This includes regular monitoring and reporting of any adverse effects as well as ensuring informed consent is obtained from all trial participants.
How does Elicio Therapeutics' technology work?
Elicio Therapeutics employs a unique antigen delivery technology that uses lipid nanoparticles to deliver cancer antigens directly to immune cells. This method is designed to activate the immune system more effectively against cancer cells, improving overall therapeutic efficacy.
Is Elicio Therapeutics publicly traded?
Yes, Elicio Therapeutics, Inc. is publicly traded on the Nasdaq under the ticker symbol ELTX. The company went public to raise funds for its research and development efforts, as well as to broaden its investor base.
What are the financial prospects for Elicio Therapeutics?
As a publicly traded company, Elicio Therapeutics focuses on securing funding through various means, including partnerships, grants, and market revenues from successful therapies. While the biotech sector can be unpredictable, advancements in their research pipeline could lead to strong financial growth.
What are the long-term goals of Elicio Therapeutics?
Elicio Therapeutics aims to advance its product candidates through various clinical phases to obtain regulatory approvals, ultimately bringing effective cancer therapies to the market. The company also aspires to expand its pipeline by developing additional therapies targeting other types of cancer.
What are the potential benefits of Elicio's immunotherapy?
The potential benefits of Elicio's immunotherapy include the ability to generate a targeted immune response against cancer, improved treatment outcomes, and possibly reduced side effects compared to traditional therapies. Their approach may enable more personalized treatment options for patients.
What does Elicio Therapeutics, Inc. do?
Elicio Therapeutics, Inc. is a biotechnology company that focuses on developing transformative immunotherapies for cancer treatment. Their proprietary technology, based on the use of proprietary antigen delivery systems, aims to trigger strong immune responses against tumors.
What is Elicio Therapeutics' lead product candidate?
Elicio's lead product candidate is ELI-002, an immunotherapy designed to improve T-cell responses against cancer. It utilizes the company's proprietary Amphiphilic Drug Delivery System to enhance immune activation specifically in tumor environments.
What is Elicio Therapeutics’ approach to commercialization?
Elicio Therapeutics takes a strategic approach to commercialization by seeking partnerships with pharmaceutical companies for marketing and distribution. The company aims to ensure that its therapies reach patients effectively and are integrated into treatment protocols within healthcare systems.
What is the current status of ELI-002?
As of the latest updates, ELI-002 is in clinical trials to evaluate its efficacy and safety as a treatment for patients with specific types of solid tumors. The company continually monitors the trial's progress and anticipates further advancements in the near future.
What is the mission of Elicio Therapeutics?
The mission of Elicio Therapeutics is to revolutionize cancer treatment through innovative immunotherapy solutions that empower the body’s own immune system to fight cancer more effectively, with the aim of improving survival rates and quality of life for cancer patients.
What regulatory approvals has Elicio Therapeutics obtained?
Elicio Therapeutics seeks to obtain the necessary regulatory approvals from agencies such as the FDA for its investigational therapies. The company is committed to complying with all regulatory guidelines throughout the clinical trial process to ensure patient safety and efficacy.
What role does research play in Elicio Therapeutics' operations?
Research is central to Elicio Therapeutics' operations, driving the development of innovative therapies. The company invests heavily in preclinical and clinical research to understand the mechanisms of action and to optimize therapeutic approaches in cancer treatment.
What types of cancer is Elicio Therapeutics focusing on?
Elicio Therapeutics primarily focuses on cancers that are difficult to treat, including melanoma, and glioblastoma. Their research targets solid tumors and aims to enhance the body’s immune response to combat these challenging forms of cancer.
When was Elicio Therapeutics, Inc. founded?
Elicio Therapeutics, Inc. was founded in 2016. The company was established with the vision to combine advanced immunotherapy techniques with innovative drug delivery systems to improve patient outcomes in cancer therapy.
Where is Elicio Therapeutics, Inc. located?
Elicio Therapeutics has its headquarters in Cambridge, Massachusetts. This location places the company in a hub of biotechnology innovation, allowing for collaboration with other leading firms and research institutions in the field.
Who are the key executives at Elicio Therapeutics?
The key executives at Elicio Therapeutics include a team of experienced professionals with backgrounds in biotechnology and pharmaceuticals. The leadership is comprised of individuals with significant expertise in drug development and commercialization in the biotech sector.
What is the current price of Elicio Therapeutics, Inc. - Common Stock?
The current price of Elicio Therapeutics, Inc. - Common Stock is 5.500
When was Elicio Therapeutics, Inc. - Common Stock last traded?
The last trade of Elicio Therapeutics, Inc. - Common Stock was at 4:00 pm EDT on April 3rd, 2025